retatrutide dosage clinical trials retatrutide Dosing Schedule: Proven 2026 Guide retatrutide clinical trial dosing frequency

Insulin resistance and oxidative stress in the brain: whats new

STEP-1 and SURMOUNT-4, How Long Results Typically Last The STEP-1 trial extension provides a stark example of what happens after treatment stops

CagriSema may become an important Novo Nordisk follow-up platform if the amylin-plus-GLP-1 combination proves durable and tolerable

However, the UPenn study published in Nature Health found that women in a large real-world dataset reported menstrual changes with enough frequency to suggest the topic warrants more systematic research

A phase II trial focusing on individuals with overweight or obesity, coupled with hypertension or dyslipidemia but without T2D, found that cagrilintide (2.4 mg) alongside diet and exercise, led to a 10% body weight reduction compared to 3% with placebo over 26 weeks [99]